Sonya is a physician with over 20 years’ experience of clinical development, advancing therapeutic programmes from first in man through to registration. Currently the Chief Medical Officer at Evox Therapeutics, Sonya has held leadership positions at Gyroscope Therapeutics and ProQR and has global development experience with Pfizer and Relypsa based in the United States.
Sonya’s extensive experience in early development includes a focus on translational medicine, leading programmes in gene therapy, biologics, including antisense RNA, and small molecules. She has led successful interactions with health authorities globally, supporting IND/CTA, first-in-class NMEs, and negotiation of a SPA leading to NDA and MAA. Sonya has an extensive network in the academic community and biopharmaceutical industry, having established strong collaborations and advisory boards. Prior to joining Evox, Sonya was most recently at Gyroscope, where she established and led clinical development, translational medicine and clinical genetics. She was responsible for defining the development strategy for the portfolio of ophthalmology gene therapies, which was the basis for a Series B financing round resulting in a £50.4 million raise.